Skip to content
Back to News Hub
CharitiesAidWelfare, Medical Health Aged Care

2 MONTHS TO GO – SAVE THE DATE

Bowel Cancer Australia < 1 mins read

June is Bowel Cancer Awareness Month

 

Bowel Cancer Australia’s signature event to raise awareness of Australia’s second deadliest cancer and funds for the leading community-funded charity dedicated to championing what matters most to people impacted by bowel cancer and empowering everyone affected to live their best life.

 

bowelcanceraustralia.org/early-onset

Helpline: 1800 727 336 (SCREEN)


Contact details:


For an interview with a medical expert or patient contact:
Stephanie Bansemer-Brown – Bowel Cancer Australia
stephanie@bowelcanceraustralia.org   |   0412 915 797

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • CharitiesAidWelfare, Government VIC
  • 31/10/2024
  • 14:04
Council to Homeless Persons

Victorians waiting longer for homes as public wait times surge

Victoria’s public housing waiting times have blown out to an average of almost 20 months for people who have been assessed as a high priority. New figures released today in the Department of Families, Fairness and Housing annual report show average wait times in 2023/24 increased to 19.8 months for people with priority access. That is 88 per cent longer than the Victorian government’s own target of 10.5 months, and a 30 per cent increase from two years ago. Council to Homeless Persons has warned the state’s dire shortage of social housing is behind the soaring wait times, which are…

  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans